Skip to content

Alpine vs. Xpedition: Evaluation of Stent Delivery System

Randomized Clinical Evaluation of Alpine® vs. Xpedition® Stent Delivery System of the XIENCE® Everolimus-eluting Stent

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03451617
Acronym
AXES
Enrollment
500
Registered
2018-03-02
Start date
2017-10-05
Completion date
2020-10-05
Last updated
2018-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Percutaneous Coronary Intervention

Brief summary

To evaluate and compare the performance of two stent delivery systems for percutaneous coronary intervention with everolimus-eluting stent.

Detailed description

Rationale: The current gold standard for percutaneous coronary intervention (PCI) is the second generation drug-eluting stent (DES). The most commonly used DES is the everolimus-eluting stent (EES). New stent delivery systems for PCI with EES are developed to optimize strength, flexibility and pushability of the catheter. The effect on procedural time of new stent delivery systems has not yet been investigated in clinical practice. Objective: To evaluate and compare the performance of two stent delivery systems for PCI with EES. Study design: Randomized comparative trial with 500 patients in the University Medical Center Groningen (UMCG). Study population: All patients undergoing PCI with EES, aged 18 years or older, will be considered for eligibility. Patients will be excluded when scheduled for chronic total occlusion (CTO) PCI or if verbal informed consent cannot be obtained. Intervention: The first group will undergo PCI with the XIENCE EES using the Alpine stent delivery system, the second group will undergo PCI with the Xpedition stent delivery system. Main study parameters/endpoints: The primary endpoint is the proportion of procedures with crossing time (from introduction of guidewire to stent deployment) longer than 30 minutes. Secondary endpoints include procedural time (from heparin administration to removal of catheter sheath, mins), use of additional materials, total procedural costs, radiation dose (μGym2), radiation time (mins), and contrast dose (ml).

Interventions

DEVICEStent delivery with Xpedition

Use of Xpedition stent delivery system to implant the XIENCE stent

DEVICEStent delivery with Alpine

Use of Alpine stent delivery system to implant the XIENCE stent

Sponsors

University of Groningen
Lead SponsorOTHER
Abbott
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients undergoing PCI with EES, aged 18 years or older

Exclusion criteria

* Chronic total occlusion (CTO) PCI * Inability to obtain (verbal) informed consent

Design outcomes

Primary

MeasureTime frameDescription
Crossing timeDuring PCI procedureProportion of procedures with crossing time (from introduction of guidewire to stent deployment) longer than 30 minutes.

Secondary

MeasureTime frameDescription
Procedural timeDuring PCI procedure
Total procedural costsDuring PCI procedureTotal cost of the materials used during the procedure (stent delivery system and additional materials) in euros.
Radiation doseDuring PCI procedure
Radiation timeDuring PCI procedure
Contrast doseDuring PCI procedure

Countries

Netherlands

Contacts

Primary ContactPim van der Harst, Prof. Dr.
p.van.der.harst@umcg.nl+31 50 3612355

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026